Bitcoin pioneer Charlie Shrem peels back the layers on the lives and backgrounds of the world's most impactful innovators. Centering around intimate narratives, Shrem uncovers a detailed, previously unspoken story of the genesis and evolution of bitcoin, cryptocurrency, artificial intelligence, and the web3 movements. Join Shrem as he journeys through the uncharted territories of tech revolutions, revealing the human side of the stories that shaped the digital world we live in today.
…
continue reading
Sisällön tarjoaa Proactive Investors. Proactive Investors tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
Player FM - Podcast-sovellus
Siirry offline-tilaan Player FM avulla!
Siirry offline-tilaan Player FM avulla!
Tryptamine Therapeutics completes phase 1b of IV-infused psilocin trial
MP3•Jakson koti
Manage episode 436376774 series 2891889
Sisällön tarjoaa Proactive Investors. Proactive Investors tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
Tryptamine Therapeutics Ltd (ASX:TYP, OTC:TYPTF) CEO Jason Carroll joins Proactive’s Tylah Tully to discuss the completion of dosing all participants in its Phase 1b IV-infused psilocin Healthy Human Volunteer Study conducted at CMAX Clinical Research in Adelaide. This trial involved the administration of TRP-8803, a proprietary IV-infused psilocin formulation, to 11 participants across three cohorts over a period of up to 150 minutes. The study aimed to refine dosing and infusion rates to maintain precise blood levels of psilocin for optimal therapeutic effects. All participants were safely discharged following treatment and dosing follow-up. This Phase 1b trial provided key insights into the blood concentration limits of psilocin required to maintain an ideal therapeutic zone. The results will support future patent applications and underpin upcoming trials targeting binge eating disorder (BED) and fibromyalgia syndrome (FMS). Carroll highlighted the trial's significance in advancing the company’s proprietary IV-infusion technology, which may overcome challenges associated with oral dosing of psychedelics. A Safety Review Council is evaluating the trial data to determine if safety criteria was met. The company will provide further updates upon review completion. Successful Phase 2a trials with TRP-8802 (oral psilocybin) have de-risked upcoming TRP-8803 trials. #Proactiveinvestors #TryptamineTherapeutics #ASX #Psilocin #ClinicalTrial #Phase1b #IVInfusion #Psychedelics #TRP8803 #TRP8802 #BingeEatingDisorder #Fibromyalgia #ClinicalResearch #CMAX #Adelaide #TherapeuticGoodsAdministration #Pharmaceutical #MentalHealth #SafetyReview #PatentApplication #DrugDevelopment #PatientSafety #Therapeutics #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
605 jaksoa
MP3•Jakson koti
Manage episode 436376774 series 2891889
Sisällön tarjoaa Proactive Investors. Proactive Investors tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
Tryptamine Therapeutics Ltd (ASX:TYP, OTC:TYPTF) CEO Jason Carroll joins Proactive’s Tylah Tully to discuss the completion of dosing all participants in its Phase 1b IV-infused psilocin Healthy Human Volunteer Study conducted at CMAX Clinical Research in Adelaide. This trial involved the administration of TRP-8803, a proprietary IV-infused psilocin formulation, to 11 participants across three cohorts over a period of up to 150 minutes. The study aimed to refine dosing and infusion rates to maintain precise blood levels of psilocin for optimal therapeutic effects. All participants were safely discharged following treatment and dosing follow-up. This Phase 1b trial provided key insights into the blood concentration limits of psilocin required to maintain an ideal therapeutic zone. The results will support future patent applications and underpin upcoming trials targeting binge eating disorder (BED) and fibromyalgia syndrome (FMS). Carroll highlighted the trial's significance in advancing the company’s proprietary IV-infusion technology, which may overcome challenges associated with oral dosing of psychedelics. A Safety Review Council is evaluating the trial data to determine if safety criteria was met. The company will provide further updates upon review completion. Successful Phase 2a trials with TRP-8802 (oral psilocybin) have de-risked upcoming TRP-8803 trials. #Proactiveinvestors #TryptamineTherapeutics #ASX #Psilocin #ClinicalTrial #Phase1b #IVInfusion #Psychedelics #TRP8803 #TRP8802 #BingeEatingDisorder #Fibromyalgia #ClinicalResearch #CMAX #Adelaide #TherapeuticGoodsAdministration #Pharmaceutical #MentalHealth #SafetyReview #PatentApplication #DrugDevelopment #PatientSafety #Therapeutics #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
605 jaksoa
Tous les épisodes
×Tervetuloa Player FM:n!
Player FM skannaa verkkoa löytääkseen korkealaatuisia podcasteja, joista voit nauttia juuri nyt. Se on paras podcast-sovellus ja toimii Androidilla, iPhonela, ja verkossa. Rekisteröidy sykronoidaksesi tilaukset laitteiden välillä.